Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the US FDA for the Treatment of Gastric and Pancreatic Cancers

Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

IMscin001 Part 2: A Randomised Phase 3, Open-label, Multicentre Study Examining the Pharmacokinetics, Efficacy, Immunogenicity, and Safety of Atezolizumab Subcutaneous versus Intravenous in Previously Treated Locally Advanced or Metastatic NSCLC

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the US FDA for the Treatment of Gastric and Pancreatic Cancers

header-info

May, 25, 2023

On May 23rd, Antengene Corporation Limited announced that ATG-022, a Claudin 18.2 antibody drug conjugate, has been granted two Orphan Drug Designations consecutively by the FDA for the treatment of gastric cancer and pancreatic cancer. To date, Antengene has received 3 ODDs from the FDA for two of its in-house products.

Access the full article to read more here.